Study tracks early adoption of liver histotripsy treatment

It has been astir 3 years since the U.S. Food and Drug Administration (FDA) cleared the HistoSonics Edison histotripsy strategy to dainty superior and metastatic liver tumors. To analyse however the technology's adoption and usage person progressed, a probe squad astatine the University of Virginia, led by Allan Tsung, M.D., prof and seat of the Department of Surgery, sought to supply an aboriginal nationalist snapshot of its usage for this indication.